Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials
The IMID Forum
- Published
- August 7, 2025
- Duration
- 17:45
- Summary source
- description
- Last updated
- Jun 21, 2026
Discusses Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of P…
Summary
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.
Intelligent report
Sign in to read teasers, or upgrade to Research Pro to commission a new dossier for this episode. Learn more →
Show notes
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.